miraDry® FAQs

miraDry Underarm Sweating Treatment Atlanta

Frequently Asked Questions


Q1 ) Are there side effects to miraDry?

Some localized soreness or swelling is normal, and typically clears within a few weeks. Some patients have temporary, short-term altered sensation in the skin of their underarms or upper arms, which gradually disappears1.


Q2 ) Are the results lasting?

Yes! Because the sweat glands don’t regenerate or grow back2 the reduction or elimination of the sweat production achieved with miraDry® is long-term.


Q3 ) Are the underarm sweat glands necessary to maintain body temperature?

Actually, no. The body contains over four million sweat glands, and only about 2% of them are in the underarms. Eliminating this 2% does not affect the body’s ability to cool itself3.


Q4 ) Does miraDry® cause compensatory sweating in other parts of the body?

No. miraDry® treatments work by disabling the eccrine glands in the underarms, and not the nerves that stimulate sweating. Following treatment, the body continues to signal to the nerves to initiate sweating, however the eccrine glands will not be able to produce sweat. The body will not send signals to other areas to “turn on” any compensatory sweatinglike other treatments such as Sympathectomy4.


Q5 ) Do the Underarm sweat glands ever grow back?

No. The underarm sweat glands don’t grow back or regenerate once they’ve been destroyed1.


Q6 ) Can miraDry® disable sweat glands elsewhere on the body?

Currently no, it is only designed and calibrated to treat underarm sweat glands for axillary hyperhidrosis. It cannot be used to treat sweating in other areas of the body such as hands, feet, forehead or knees.


Q7 ) Is miraDry® safe?

Yes! The miraDry® procedure is FDA approved5 and has been performed successfully on thousands of patients, and it’s been proven to be highly safe and effective3.


1. Glaser D., Coleman W., Fan L., Kaminer M., Kilmer S., Nossa R., Smith S., O’Shaughnessy K., (2012). A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatologic Surgery. 2012 Feb;38(2):185-91. doi: 10.1111/j.1524-4725.2011.02250.x. Epub 2012 Jan 30. https://www.ncbi.nlm.nih.gov/pubmed/22289389
2. Li H., Zhou G., Fu X., Zhang L., (2009). Antigen expression of human eccrine sweat glands. Therapeutic Options. Journal of Cutaneous Pathology. 36(3):318-324, March 2009. https://www.ncbi.nlm.nih.gov/pubmed/19032382
3. Taylor N., Machado-Moreira C., (2013). Regional variations in transepidermal water loss, eccrine sweat gland density, sweat secretion rates and electrolyte composition in resting and exercising humans. Extreme Physiology & Medicine. 2013; 2:4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710196/
4. Nawrocki S., Cha J., (2019). The Etiology, Diagnosis and Management of Hyperhidrosis: A Comprehensive Review. Part II. Therapeutic Options. Journal of the American Academy of Dermatology. 2019 Jan 30. pii: S0190-9622(19)30167-7. doi: 10.1016/j.jaad.2018.11.066. https://www.ncbi.nlm.nih.gov/pubmed/30710603
5. Melkerson, Mark. “Re: K103014.” Department of Health & Human Services, Food and Drug Administration. 20 January 2011. Letter. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103014.pdf
About the Author

Charlotte Kulkin, RN, CNS, FNP-BC

Charlotte Kulkin, RN, CNS, FNP-BC, is a Family Nurse Practitioner licensed by the State of Georgia, and the Georgia Composite Medical Board. Charlotte has more than 30 years of experience in primary care, critical care, and cardiac rehabilitation. She currently serves as WIFH’s miraDry® specialist, performing over 600 miraDry® procedures since 2015.